Insights
Insights From Our Experts
Articles
Making Cutting-Edge Cancer Treatments Accessible: Advancing CAR-T Therapy to the Community Practice
Posted by
Anne Marie Robertson , Barry Vucsko , Jordan Schell , Vanitha Sankaran, PhD , Jordan Hayes on March 12, 20253/12/25
This article explores the significant advancements in CAR-T therapy and its transition from academic centers to community practices. CAR-T therapy, a revolutionary treatment for certain hematological malignancies, involves modifying a patient’s T-cells to target and destroy…
The Path to Maximizing Revenue: How to Simplify Pharmaceutical Commercialization and Find Optimum Success
For pharmaceutical manufacturers, achieving optimal revenue in a competitive landscape is a multifaceted challenge that requires strategic foresight and meticulous execution. Small and emerging biotech companies often face significant hurdles in reaching maximum commercial success. In…
Successfully Navigating the Complexity of Market Access Across Europe to Improve Health Equity
Navigating the complexities of bringing new drug therapies to market in Europe is a formidable challenge, especially with the diverse and fragmented reimbursement landscape across the EU’s 27 member states. In this insightful article published in…
Securing Launch Success Within the Context of the New EU Health Technology Assessment Regulation (HTAR) Landscape in Europe
The EU Health Technology Assessment Regulation (HTAR), effective from January 12, 2025, aims to harmonize the evaluation of health technologies across member states to enhance patient access to innovative treatments. In this latest article from Pamela…
Transformative Commercialization for New Biopharma Entrants: Ensuring Success With Capital and Time Efficiency
Discover the transformative power of EVERSANA’s innovative commercialization model in this white paper. This essential guide is ideal for pharmaceutical companies, particularly first-time launchers, aiming to navigate the complexities of product commercialization. It addresses the major…
Next-Generation Brand Planning: Some (Unexpected) Worrying Trends Demand a Rethink on Brand Planning
In our third annual report on the state of brand planning, EVERSANA surveyed nearly 100 brand planning executives across biopharmaceuticals, diagnostics and medical devices. This year, we expanded our assessment by hosting 111 marketing leaders from…
The AI Revolution: 7 Trends Shaping the AI Revolution in 2025
We’re just weeks into 2025, and already, the landscape of artificial intelligence (AI) continues to evolve at an unprecedented pace, reshaping industries and redefining possibilities. In the realm of healthcare, AI is not just a buzzword;…
Point-of-Care (POC) Diagnostics: Transformation From Pre- to Post- Pandemic: An Asian Perspective
Authors: Dr. Shaillender M, Engagement Manager, EVERSANA APAC; Robin Arnold, Executive Vice President, EVERSANA APAC; Aditya Prakash, Consultant, EVERSANA APAC The pandemic significantly accelerated the adoption and technological advancement of point-of-care (POC) diagnostics, transforming them from…
The Evolution of Digital Health Policy: A 2024 Retrospective and 2025 Outlook
The landscape of digital health policy continues to evolve, with significant advancements shaping the regulatory and reimbursement frameworks. Here are some of the key developments that occurred during 2024 as well as our predictions for what…
Beyond Theory: Integrated Commercialization Model Proves Valuable in Launch Success
Unlock the Future of Drug Commercialization Discover the Proven Strategies Behind Successful Drug Launches Are you ready to revolutionize your drug commercialization approach? Download our exclusive whitepaper, “Beyond Theory: Integrated Commercialization Model Proves Valuable in Launch Success,” and…